IGM Biosciences is pivoting its strategy to focus on developing T cell-engaging IgM antibodies for autoimmune diseases. The company will cut spending on its oncology programs, including aplitabart, and reduce its workforce. This strategic shift comes as IGM sees significant potential in the autoimmune space and aims to extend its cash runway into 2027.